Clinical trials: HLA Sensitization
Kidney Transplantation Recipients, HLA Sensitization
Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%
This study is a prospective, open-label, two-arm exploratory clinical trial aimed at evaluating the safety and efficacy of Bispecific T-cell Engager (BiTE) therapies in refractory, highly sensitized kidney transplant candidates.
- Trial name
- NCT07689149
- Testing
- BiTE (CD19 x CD3 Bispecific Antibody), BiTE (BCMA x CD3 Bispecific Antibody)
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Severely Burned Patients
HLA Sensitization in Severely Burned Patients
Primary goal of this study is the analysis of HLA (Human leucocyte antigen) formation in severly burned patients. Potential HLA triggers in the treatment of severely burned patients are blood products, assist devices or temporary…
- Trial name
- NCT02537821
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
HLA Sensitization
Desensitization in Kidney Transplantation
To determine if deletional strategies will provide effective desensitization.
- Trial name
- NCT00908583
- Testing
- plasmapheresis, Bortezomib, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Cincinnati
Highly Sensitized Patients Awaiting Kidney Transplant
OM336 in Sensitized Transplant Candidates
This investigator-initiated, single-arm, open-label Phase IIa pilot study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OM336 in highly HLA-sensitized adults with chronic…
- Trial name
- NCT07789431
- Testing
- OM3436
- Where
- 2 sites in Austria, Germany
- Volunteers
- 12 people
- Sponsor
- Medical University of Vienna
Kidney Transplant Rejection
Immune Response in Desensitized Patients
Kidney transplantation is the best treatment for chronic renal failure in terms of morbidity and mortality, quality of life for patients and health economics.
- Trial name
- DELIGHT (NCT05785936)
- Testing
- Desensitization
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Transplant Sensitization, Panel Reactive Antibody
An In-vitro Standardization of B Cell Elispot Assays
This study is being done because the study doctor is trying to develop a new test which will help transplant doctors monitor patients with high panel reactive antibodies (PRA).
- Conditions
- Transplant Sensitization, Panel Reactive Antibody, Sensitization to HLA Antigens
- Trial name
- NCT01334281
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Sensitisation, Highly Sensitised Dialysis Patients
The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation
While the number of kidney transplants is increasing worldwide every year, there is a clear imbalance between the high number of patients in the waiting list and those receiving a transplant and importantly, among waitlist…
- Trial name
- COMBAT (NCT05145296)
- Testing
- Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Grenoble
Kidney Failure, Chronic, Kidney Transplantation
Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)
The purpose of this clinical trial is to evaluate whether a temporary reprogramming of the immune system can help highly sensitized (hyperimmunized) patients with end-stage kidney disease safely receive a compatible kidney…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Alloimmunization, HLA Sensitization
- Trial name
- HIPER-RESET (NCT07607197)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Kidney Transplant
Alloreactive Memory B Lymphocytes and Anti-HLA Sensitization
In transplantation, B lymphocytes are major cellular players in the alloreactive humoral response through the production of antibodies targeting allogeneic HLA molecules expressed by the transplant.
- Trial name
- ALLO-BMEM (NCT07011238)
- Testing
- Patients meeting HLA immunization criteria
- Where
- France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Rouen
Kidney Transplantation, Immunosuppressive Agents
Anti-HLA Immunization And Immunosuppressive Therapy Management In Kidney Transplant Patients Returning to Dialysis
This study is an analytical observational retrospective cohort study. It is a single-center study conducted in the Nancy University Hospital. End stage renal disease is the ultimate stage of the chronic kidney disease.
- Conditions
- Kidney Transplantation, Immunosuppressive Agents, HLA Sensitization, Dialysis
- Trial name
- NCT05282875
- Testing
- management of immunosuppressive therapy
- Where
- France
- Volunteers
- 430 people
- Sponsor
- Central Hospital, Nancy, France
Bone Cancer
HLA Sensitization Following Major Cortical Allograft Bone Procedures
The purpose of this study is to find out whether or not antibodies to the donor bone are present in the blood of patients who receive the donor bone.
- Trial name
- NCT00160719
- Testing
- retrieve blood samples
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
HLA/AAV Sensitization, Auto-immune Diseases
Real-world Clinical Effectiveness & Safety LV009, an in Vivo CAR-T for the Treatment of Hematologic Cancers, Auto-immune Diseases & HLA/ AAV Sensitization.
The study objective is to determine the real-world safety and effectiveness of LV009 therapy for 3 potential indications: (1) refractory or relapsed hematologic cancers (acute lymphoblastic Leukemia, B cell Lymphomas, multiple…
- Conditions
- HLA/AAV Sensitization, Auto-immune Diseases, Hematologic Cancers
- Trial name
- LV009 (NCT07873476)
- Testing
- LV009
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- Healthy Malaysia Association
Cardiac Transplant
Daratumumab in HLA Desensitization Prior to Transplantation
The purpose of this study is to learn about how well the drug daratumumab/hyaluronidase-fihj (DARZALEX Faspro™) helps to lower high levels of HLA (Human Leukocyte Antigen) antibodies in a person waiting for a heart transplant.
- Trial name
- NCT05300451
- Testing
- Daratumumab and hyaluronidase-fihj
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Barry A. Boilson
Renal Failure , Chronic, Graft Failure
Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure
The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression…
- Conditions
- Renal Failure , Chronic, Graft Failure, Graft Rejection, Allograft
- Trial name
- NCT06676696
- Testing
- Continue low dose calcineurin inhibitor (CNI), Calcineurin inhibitor withdrawal at 6 months
- Where
- Spain
- Volunteers
- 202 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446459
- Testing
- mycophenolate mofetil (CellCept)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington